Why Institutional Money Is Rotating Into These Underpriced Japanese Large Caps

Global investors are watching oil prices closely as they influence inflation and interest rate expectations. When energy markets stay unsettled, many stocks with strong cash flow potential can slip to prices that do not fully reflect their underlying value. That is where the Undervalued Stocks Based On Cash Flows screener becomes useful. This article highlights three stocks from the screener that stand out on cash flow and valuation grounds.

The stocks covered below are just a small sample, and the full screen surfaced 59 more companies with equally compelling cash flow stories that are not included in this article. If you want to identify and analyze the highest conviction opportunities right now, head straight to the Undervalued Stocks Based On Cash Flows screener.

Chugai Pharmaceutical (TSE:4519)

Chugai Pharmaceutical is a Japan based drug company that develops, manufactures and sells prescription medicines, with a strong focus on oncology and complex biologic therapies. It currently reports essentially all of its ¥1,342.8b in revenue from pharmaceuticals, giving it a clear, single segment focus. The company is large in scale with a market cap of about ¥11.3t, which places it among the bigger listed healthcare stocks globally.

Investors looking at Chugai Pharmaceutical today are seeing a business with high profitability and strong cash generation. The stock is flagged by the screener as trading well below an estimated cash flow based value. Earnings growth has been solid, helped by biologic drugs like Hemlibra and Actemra, and new AI assisted research partnerships such as the Phylo Biomni Lab tie up are aimed at making future drug discovery more efficient. The flip side is meaningful concentration in a handful of therapies, ongoing pricing and regulatory pressure, and reliance on Roche for key functions. If those strengths and weaknesses are balanced correctly, the recent earnings beat, higher dividend and updated guidance could be setting up a very interesting story for long term holders.

Chugai Pharmaceutical’s cash rich, focused drug portfolio could be telling a different story to its current share price. Get the full picture on cash flows, valuation tensions and a crucial pipeline risk hiding in the DCF valuation analysis for Chugai Pharmaceutical

Build your own cash flow focused shortlist

Chugai Pharmaceutical and the two other stocks in this article all came from a single screener, but the real opportunity is in shaping your own filters. Use our flexible Screener to mix cash flows, valuation, growth and balance sheet strength, or start with any of our curated Investing Ideas for ready made stock shortlists.

JX Advanced Metals (TSE:5016)

JX Advanced Metals is a Japan based materials company that supplies copper and rare metal products used in semiconductors, electronics and recycling, including copper alloys and foils, sputtering targets, compound semiconductors, high purity metals and titanium sponge. It has a long operating history going back to 1905 and is now valued at roughly ¥3.7t, placing it firmly in large cap territory.

JX Advanced Metals appears on this cash flow focused list because earnings momentum and valuation are pulling in the same direction. Net income of ¥104,645 million on ¥884,638 million of sales for the year to March 2026 points to a 14.6% margin, and earnings over the past year grew much faster than the wider Japanese metals and mining industry. The stock is flagged as trading about 21.4% below an estimated fair value. Forecasts indicate double digit earnings growth and strong future ROE. The share price has been very volatile in recent months and the top team is relatively new, which raises valid questions. At the same time, sizeable buybacks completed in June 2026 and new index inclusions indicate that the full JX Advanced Metals story may not be reflected in the current price.

JX Advanced Metals has earnings and valuation pulling apart in a way many investors may be underestimating. Get the full story in the analyst forecasts for JX Advanced Metals to understand the twist behind those margins and buybacks.

Murata Manufacturing (TSE:6981)

Murata Manufacturing is a global supplier of ceramic based electronic components that sit inside equipment such as smartphones, cars, data centers and industrial systems. Most of its roughly ¥1,253.6b in product revenue comes from Components at about ¥1,250.6b, with Devices and Modules adding around ¥664.8b and a small ¥71.5b tagged as Others. The company is large in scale with a market cap of about ¥13.2t, putting it among Japan’s bigger listed electronics stocks.

Murata Manufacturing operates in areas such as 5G, automotive electronics and data center demand. Forecast earnings growth above 20% a year and improving profit margins are paired with a share price that screens as below estimated cash flow value, which is an unusual mix for a components supplier of this size and profile. The catch is a volatile stock price, a relatively high P/E and a funding mix that leans on external borrowings, so investors are taking on a degree of risk. Investors who can look beyond near term swings may find the current setup for Murata Manufacturing worth a closer look.

Growth, valuation and volatility are pulling apart for Murata Manufacturing, and many investors may be missing what that signals about the next chapter. Get the full context in the analyst forecasts for Murata Manufacturing

Seeking Fresh Alternatives Beyond These Stocks

Some of the most interesting stories break out quietly while attention sits elsewhere. Before the next wave gains momentum or gets caught by the crowd, scan these fresh ideas and consider your options.

• Identify stronger balance sheets before others notice by scanning the curated list of solid balance sheet and fundamentals (40 results) that still appear under the radar for now.
• Review the hand picked 29 elite gold producer stocks to explore potential sector rotations into hard assets if attention shifts back to producers.
• Explore the focused 89 nuclear energy infrastructure stocks to follow the energy transition theme while the story is still building.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com